1676893-24-5

Basic information

• Product Name: NSC781406
• Synonyms: NSC781406
• CAS NO: 1676893-24-5
• Molecular Formula: C29H27F2N5O5S2
• Molecular Weight: 627.6819864
• Mol File: 1676893-24-5.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 775.1±70.0 °C(Predicted)
• Appearance: /
• Density: 1.52±0.1 g/cm3(Predicted)
• PKA: 6.23±0.40(Predicted)
• CAS DataBase Reference: NSC781406(CAS DataBase Reference)
• NIST Chemistry Reference: NSC781406(1676893-24-5)
• EPA Substance Registry System: NSC781406(1676893-24-5)

Safety Data

• Hazardous Substances Data: 1676893-24-5(Hazardous Substances Data)

Usage

Description

NSC 781406 is a dual inhibitor of PI3K and mammalian target of rapamycin (mTOR; IC50s = 2.0, 9.4, 2.7, 14, and 5.4 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ, and mTOR, respectively). It inhibits cell growth in the NCI-60 panel of cancer cell lines (mean GI50 = 65 nM). NSC 781406 (30 mg/kg) reduces tumor volume in a BEL-7404 hepatic cancer mouse xenograft model.

Upstream product

• 1086063-46-8 N-(5-bromo-2-methoxypyridine-3-yl)-2,4-difluorobenzene sulfonyl chloride 
• 884495-39-0 5-bromo-2-(methyloxy)-3-pyridinamine 
• 1083326-73-1 N-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide 
• 199538-99-3 tert-butyl 4-(prop-2-yn-1-yl)piperazine-1-carboxylate 
• 152684-30-5 5-bromo-2-methoxy-3-nitropyridine 
• 67443-38-3 5-bromo-2-chloro-3-nitropyridine 

Relevant articles and documents

Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma

The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway is related to cellular activities. Abnormalities of this signaling pathway were discovered in various cancers, including hepatocellular carcinoma (HCC). The PI3K/mTOR dual inhibitors were proposed to have enhanced antitumor efficacies by targeting multiple points of the signaling pathway. We synthesized a series of propynyl-substituted benzenesulfonamide derivatives as PI3K/mTOR dual inhibitors. Compound 7k (NSC781406) was identified as a highly potent dual inhibitor, which exhibited potent tumor growth inhibition in the hepatocellular carcinoma BEL-7404 xenograft model. Compound 7k may be a potential therapeutic drug candidate for HCC.